Drugs / ATIR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT00967343 | Aug 2009 → Feb 2012 | myelodysplastic syndrome, myeloid leukemia, plasma cell myeloma, precursor lymphoblastic lymphoma/leukemia | Kiadis Pharma | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATIR | “Donor Lymphocytes Depleted of Alloreactive T-cells (ATIR), Through the Use of TH9402 and Light Treatment in an ex Vivo Process” NCT00967343 ↗ |
| Action | Deplete | “depleted of functional host alloreactive T-cells” NCT00967343 ↗ |
| Modality | Cell therapy | “donor lymphocyte preparation” NCT00967343 ↗ |
| Route | Intravenous | “Single intravenous infusion with 2x10E6 T-cells/kg” NCT00967343 ↗ |